Cargando…

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

SIMPLE SUMMARY: Tumor immune evasion is mediated in large part by the inhibition of anti-tumor T cell responses. Both the induction of tumor antigen-specific T cells and the activation state of T effector cells may be attenuated by surface receptors, which upon binding to counter receptors on immuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuske, Michael, Haist, Maximilian, Jung, Thomas, Grabbe, Stephan, Bros, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996886/ https://www.ncbi.nlm.nih.gov/pubmed/35406483 http://dx.doi.org/10.3390/cancers14071710

Ejemplares similares

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
por: Haist, Maximilian, et al.
Publicado: (2023)

The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment
por: Haist, Maximilian, et al.
Publicado: (2021)

Neutrophil-Specific Knockdown of β2 Integrins Impairs Antifungal Effector Functions and Aggravates the Course of Invasive Pulmonal Aspergillosis
por: Haist, Maximilian, et al.
Publicado: (2022)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2022)

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2021)

RhoA as a Key Regulator of Innate and Adaptive Immunity
por: Bros, Matthias, et al.
Publicado: (2019)

Nanodrugs Targeting T Cells in Tumor Therapy
por: Haist, Maximilian, et al.
Publicado: (2022)

Inhibitors of the Actin-Bundling Protein Fascin-1 Developed for Tumor Therapy Attenuate the T-Cell Stimulatory Properties of Dendritic Cells
por: Zeyn, Yanira, et al.
Publicado: (2022)

Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study
por: Mayer, Arnulf, et al.
Publicado: (2020)

Counteracting Immunosenescence—Which Therapeutic Strategies Are Promising?
por: Hieber, Christoph, et al.
Publicado: (2023)

Harnessing the Immunomodulatory Properties of Bacterial Ghosts to Boost the Anti-mycobacterial Protective Immunity
por: Lim, Jieling, et al.
Publicado: (2019)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
por: Li, Haohao, et al.
Publicado: (2022)

Interleukin-1 Beta—A Friend or Foe in Malignancies?
por: Bent, Rebekka, et al.
Publicado: (2018)

β2 Integrins—Multi-Functional Leukocyte Receptors in Health and Disease
por: Bednarczyk, Monika, et al.
Publicado: (2020)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
por: Stege, H. M., et al.
Publicado: (2021)

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells
por: Hajek, Eva, et al.
Publicado: (2018)

Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis
por: Wang, Peng-Mei, et al.
Publicado: (2023)

Sick Sinus Syndrome: More Than a Needle-in-a-haystack Manifestation of Immune Checkpoint Inhibitor-associated Myocarditis
por: Kadowaki, Hiroshi, et al.
Publicado: (2022)

Response to primary chemoradiotherapy of locally advanced oropharyngeal carcinoma is determined by the degree of cytotoxic T cell infiltration within tumor cell aggregates
por: Haist, Maximilian, et al.
Publicado: (2023)

The Role of LFA-1 for the Differentiation and Function of Regulatory T Cells—Lessons Learned from Different Transgenic Mouse Models
por: Klaus, Tanja, et al.
Publicado: (2023)

Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors
por: Stickdorn, Judith, et al.
Publicado: (2022)

Friend virus limits adaptive cellular immune responses by imprinting a maturation-resistant and T helper type 2-biased immunophenotype in dendritic cells
por: Shen, Limei, et al.
Publicado: (2018)

The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
por: Stege, Henner, et al.
Publicado: (2021)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery
por: Bros, Matthias, et al.
Publicado: (2018)

Cardiotoxicity from immune checkpoint inhibitors
por: Michel, Lars, et al.
Publicado: (2019)

Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells
por: Bednarczyk, Monika, et al.
Publicado: (2021)

CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis
por: Teschner, Daniel, et al.
Publicado: (2019)

A Trifunctional Dextran-Based Nanovaccine Targets and Activates Murine Dendritic Cells, and Induces Potent Cellular and Humoral Immune Responses In Vivo
por: Shen, Limei, et al.
Publicado: (2013)

Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
por: Kuske, Marvin, et al.
Publicado: (2018)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
por: Archilla-Ortega, Adrià, et al.
Publicado: (2022)

Indicators of responsiveness to immune checkpoint inhibitors
por: Shields, Bradley D., et al.
Publicado: (2017)

Impaired Treg-DC interactions contribute to autoimmunity in leukocyte adhesion deficiency type 1
por: Klaus, Tanja, et al.
Publicado: (2022)

Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy
por: Cone, Eugene B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rbmb7fdk9j07aitvkdm0pcnrbu